EN | RU
EN | RU

Help Support

Back

Novel BTK inhibitor exhibits promising efficacy and safety in chronic spontaneous urticaria

Chronic spontaneous urticaria Chronic spontaneous urticaria
Chronic spontaneous urticaria Chronic spontaneous urticaria

What's new?

Remibrutinib was safe and effective to treat chronic spontaneous urticaria.

Patients with chronic spontaneous urticaria treated with Remibrutinib, a new Bruton’s tyrosine kinase (BTK) inhibitor, had reduced disease activity and sustained improvements throughout the treatment. Moreover, it illustrated a favorable safety profile across the entire dose range in a randomized, dose-finding, placebo-controlled, Phase 2b, double-blind study. Researchers sought to describe the dose-response and assess the safety and effectiveness of Remibrutinib in urticaria management.

Urticaria patients that were not adequately managed by second-generation H1-antihistamines, whether they previously had anti-immunoglobulin E therapy or not, were included. Remibrutinib was administered to patients at doses of 10, 35, or 100 mg once day (q.d.), 10 mg two times a day (b.i.d.), 25 mg twice daily (b.i.d.), or a placebo (1:1:1:1:1:1:1 ratio). The primary outcomes ascertained were safety and weekly alteration in baseline Urticaria Activity Score (UAS7) from Week 4.

A total of 311 subjects were randomized. All Remibrutinib dosages were associated with decreased symptom scores from Week 1 to Week 12, with UAS7 alteration from baseline at Week 4 being -19.1 (10 mg q.d.), -19.1 (35 mg q.d.), -14.7 (100 mg q.d.), -16.0 (10mg b.i.d.), -20.0 (25 mg b.i.d.), -18.1 (100 mg b.i.d.), and -5.4 for placebo, as shown in Figure 1:

The majority of side effects lacked a dose-dependent pattern and were mild to moderate. With a quick onset of action and a promising safety profile, Remibrutinib was successful in managing chronic spontaneous urticaria across the whole dosage range.

Source:

Journal of Allergy and Clinical Immunology

Article:

Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria

Authors:

Marcus Maurer et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: